Applications for authorisation under REACH

Authorisation is one of the REACH processes for managing the risks of hazardous substances. It aims to ensure that risks from substances of very high concern (SVHCs) are properly controlled and that these substances are progressively replaced by suitable alternatives, without introducing unwanted disruptions to the functioning of the internal market. Therefore, it is possible to apply for an authorisation for a substance included in the Authorisation List (i.e. Annex XIV of the REACH Regulation).

The Authorisation procedure is described in Title VII of the REACH Regulation (EC) No. 1907/2006.
THE AUTHORISATION PROCEDURE

The uses of substances on the Authorisation list in the EU are suspended after the so-called sunset date, which is set on a case-by-case basis for each substance. Unless an exception applies, these substances may only be placed on the market if an authorisation has been granted for a specific use.

The Commission decides on the granting or refusing of authorisations. For that, ECHA’s Committees for Risk Assessment (RAC) and Socio-economic Analysis (SEAC) provide the Commission with opinions on applications for authorisation.

The up-to-date Authorisation List is available on ECHA’s website.

SUPPLY CHAIN CONSIDERATIONS

A manufacturer, an importer or a downstream user of a substance on the Authorisation List may prepare an application for authorisation for its own uses or for the uses for which they intend to place the substance on the EU market. A duly mandated only representative of a non-EU manufacturer can also submit an application.

The supply chain coverage of an authorisation is important to consider:

- If a manufacturer, a manufacturer’s only representative or an importer applies:

  Manufacturer/Importer (applicant) → Formulator → Downstream user → End user

- Manufacturer/Importer Applicant’s immediate supplier, M/I has no use itself

  Manufacturer/Importer (applicant) → Formulator → Downstream user → End user

- Manufacturer/Importer Formulator Downstream user

  Manufacturer/Importer (applicant) → Formulator → Downstream user (applicant) → End user

Figure 1. Authorisation: supply chain coverage. The arrows indicate authorisation coverage. Note: Formulators are also downstream users.

The authorisation can cover the manufacturer’s, the manufacturer’s only representative’s or the importer’s downstream uses of the substance for its customer base (“top-down” coverage).

- If a downstream user applies: The authorisation has a limited coverage. It covers the applicant itself, its customers (down the supply chain) and its immediate supplier (one level up in the supply chain) if this supplier is only placing the substance on the market (not using the substance itself). A downstream user cannot therefore cover actors up its supply chain other than the substance manufacturer or importer, this one being its immediate supplier.

THE IMPORTANCE OF DOWNSTREAM USERS AND SUPPLY CHAIN COMMUNICATION

Compared to manufacturers, only representatives or importers, downstream users may have a greater interest in ensuring that an authorisation is granted if they depend on particular substances being available. This does not mean that all downstream users should apply for an authorisation themselves. However, it does imply that manufacturers and downstream users of chemicals should communicate from the outset to share information (including the chemical safety report) and discuss the most efficient form of cooperation. In the authorisation process, communication along the supply chain is a key function.
HOW IS AN AUTHORISATION GRANTED OR REFUSED?

The criteria for granting an authorisation are defined in Art. 60 of REACH:

- Under the “adequate control route” (Art. 60(2)) an application shall be granted if the risk to human health and the environment from the use of the substance arising from the intrinsic properties specified in the Authorisation List is adequately controlled.
- Under the “socio-economic route” (Art. 60(4)), an authorisation may be granted if it is shown that the socio-economic benefits outweigh the risk to human health and the environment from the use of the substance and there are no suitable alternative substances or technologies.

The factors to be taken into account for assessing the availability of suitable alternatives are described in Art. 60(5) and in the Guidance on Applications for Authorisation.

The Committees prepare their draft opinions for the application for authorisation within 10 months of receipt of the application. The opinions are based on the application, as well as any information received during the public consultation on possible alternatives, any further information on alternatives requested by SEAC from interested parties and any further information from the applicant requested by RAC and SEAC. Applicants can comment on the draft opinions before they are adopted by the Committees.

Within three months of receipt of the Committees’ opinions, the Commission prepares a draft decision as to whether or not the authorisation should be granted. Subsequently, the Commission adopts the decision granting or refusing the authorisation.

PREPARING APPLICATIONS FOR AUTHORISATION

ECHA’s guidance and manuals illustrate how to apply for an application for authorisation and explain how to prepare the different parts of an application:

» Guide on how to apply for authorisation
» How to describe uses in the context of Authorisation
» Guidance on the preparation of an Application for Authorisation
» Guidance on Socio-Economic Analysis: Authorisation
» Guidance on information requirements and chemical safety assessment

To prepare an application for authorisation in IUCLID:

» Manual on how to prepare an application for authorisation

Formats

The format for an application for authorisation is an IUCLID dossier, to which assessment reports and supporting documents need to be attached. These are summarised below. All the formats and detailed instructions are available on ECHA’s website.

ECHA provides formats to be used by applicants for authorisation as necessary and applicable:

- Chemical safety report: documenting the chemical safety assessment of the substance and demonstrating the adequate control or minimisation of the risk arising from the use of the substance applied for.
- Analysis of alternatives: showing whether there are any suitable alternative substance(s) or technology(ies) to the substance(s) for the uses applied for.
- Socio-economic analysis: gathering socio-economic arguments in support of the application for each use of the substance applied for.

For threshold substances where adequate control is demonstrated and where suitable alternative(s) is(are) available to the user:

- Substitution plan: showing the applicant’s commitment to take the actions needed to substitute the substance with suitable alternative substance(s) or technology(ies) for the use(s) applied for within a specified timetable.

Notification of intent and pre-submission information session

ECHA recommends the potential applicants to notify well in advance their intention to submit an application. ECHA also gives the opportunity to future applicants to ask for a pre-submission information session. Here ECHA staff members respond to case-specific questions regarding the regulatory and procedural aspects of the application process.

Pre-submission information sessions should be held at least about six months before submitting an application.
Submission windows
ECHA establishes specific windows for submitting applications for authorisation (see ECHA website). Submitting the applications within these windows ensures the minimum processing time for the applications by ECHA and its Committees.

Fees and reductions for small and medium-sized enterprises
A fee has to be paid to ECHA for the development of the opinion by ECHA’s Committees. A Fee Calculator is available on ECHA website.

The level of the fee depends on the number of uses and exposure scenarios, substances and applicants covered by the application. Micro, small and medium-sized enterprises (SMEs) can get up to 90% reduction on the application fee provided that they qualify for this.

ECHA verifies the SME status of all applicants. If it concludes that the size of a company is larger than claimed when applying for authorisation, the applicant needs to pay the difference in authorisation fee as well as an administrative charge.

PUBLIC CONSULTATION ON ALTERNATIVES
The purpose of the public consultation is to gather additional, relevant and meaningful information on possible alternatives for the uses applied for. It offers the opportunity for public engagement in the regulatory process. ECHA’s scientific committees take into account the information submitted by interested third parties in the development of their opinions.

For each combination of applicant/substance/use applied for, a public consultation on alternatives is launched. The consultation lasts eight weeks, starting from the publication on ECHA’s website of the “broad information on uses”.

REVIEW REPORTS
The Commission grants the authorisations so that they are subject to a time limited review. Thus, the authorisation holder needs to submit a review report 18 months before the end of the review period, if it has not found a suitable substitute and sees the need to continue using the substance in the EU. The Guide on how to apply for authorisation gives instructions for this.

FURTHER INFORMATION
More information is available at:

» https://echa.europa.eu/regulations/reach/authorisation/applications-for-authorisation

» http://echa.europa.eu/applying-for-authorisation